Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Hypertrophic Cardiomyopathy Market

DelveInsight’s ‘Hypertrophic Cardiomyopathy (HCM)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hypertrophic Cardiomyopathy (HCM) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HCM symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Hypertrophic Cardiomyopathy (HCM) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Hypertrophic Cardiomyopathy (HCM) Disease Understanding and Treatment Algorithm

Hypertrophic Cardiomyopathy (HCM) Overview

Hypertrophic cardiomyopathy (HCM) is a common genetically inherited heart disease and represents an important cause of cardiovascular morbidity and mortality in patients of all ages. HCM is characterized by left ventricular hypertrophy unexplained by secondary causes and a non-dilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical, with the most severe hypertrophy involving the basal interventricular septum (Marian & Braunwald, 2017).

 

Although the onset of symptoms can occur at any age, typically, symptoms begin between the ages of 20 and 40. Symptoms vary but result from left ventricular outflow tract (LVOT) obstruction, diastolic dysfunction, myocardial ischemia, and supraventricular and ventricular arrhythmias. The histological features of HCM include myocyte hypertrophy and disarray, as well as interstitial fibrosis. Hypertrophy is also frequently associated with left ventricular diastolic dysfunction. In the majority of patients, HCM has a relatively benign course. However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adults. Non-sustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major risk factors for sudden cardiac death. This complication can usually be averted by the implantation of a cardioverter-defibrillator in high-risk patients. In addition, atrial fibrillation (AF) is also a common complication and is not well tolerated.

 

The diagnosis of HCM is based predominantly on echocardiographic variables, including dynamic LVOTO, LVH, distribution of increased muscle thickness, mechanism and severity of MR, and degree of diastolic dysfunction. Current indications for surgical intervention include symptomatic patients refractory to medical therapy who can tolerate the risk of surgery and patients with marked outflow gradients, even if asymptomatic. The routine applications of genetic testing and preclinical identification of family members represent an important advance. The genetic discoveries have enhanced understanding of the molecular pathogenesis of HCM and have stimulated efforts designed to identify new therapeutic agents (Hensley et al., 2015).

 

Pharmacologic therapy remains the cornerstone of treatment for alleviating HCM symptoms, including using β-adrenergic receptor blocker to blunt the heart rate, increase diastolic filling time, restore cardiac filling pressure and attenuate exercise. Disopyramide may be added to reduce symptoms in patients with LVOTO via its negative inotropic effect.

 

Despite tremendous strides in improving care for patients suffering from HCM, there remains a significant burden of disease. In recent years, we the emergence of novel pharmacotherapies, minimally‐invasive procedures, and gene‐directed approaches with the potential to fundamentally alter the therapeutic landscape.

 

Hypertrophic Cardiomyopathy (HCM) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Hypertrophic Cardiomyopathy (HCM) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Hypertrophic Cardiomyopathy (HCM) market report gives a thorough understanding of HCM symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HCM treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Hypertrophic Cardiomyopathy (HCM) Epidemiology

The epidemiology division’s Hypertrophic Cardiomyopathy (HCM) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypertrophic Cardiomyopathy (HCM) epidemiology segmented as the Total Prevalent Cases of Hypertrophic Cardiomyopathy (HCM), Diagnosed Cases of HCM, Gender Specific Prevalence of HCM, Type Specific Diagnosed Cases of HCM. The report includes the prevalent HCM scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Hypertrophic Cardiomyopathy (HCM) Epidemiology

The epidemiology segment also provides the Hypertrophic Cardiomyopathy (HCM) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM diagnosed patient population of Hypertrophic Cardiomyopathy (HCM) were 227,354 in 2020.

Hypertrophic Cardiomyopathy (HCM) Drug Chapters          

The drug chapter segment of the Hypertrophic Cardiomyopathy (HCM) report encloses the detailed analysis of HCM marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Hypertrophic Cardiomyopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Hypertrophic Cardiomyopathy (HCM) Emerging Drugs

 

Mavacamten: Bristol Myers Squibb

Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance.

 

In clinical and preclinical studies, mavacamten has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance.  MyoKardia is developing mavacamten to treat conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause.  Mavacamten is initially being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Based on its mechanism of action and evidence of therapeutic activity, mavacamten is also being studied in the clinic to treat symptomatic non-obstructive HCM and among a targeted population of patients with heart failure with preserved ejection fraction (HFpEF).

Products detail in the report…

Hypertrophic Cardiomyopathy (HCM) Market Outlook

The Hypertrophic Cardiomyopathy market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Hypertrophic Cardiomyopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of HCM market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Hypertrophic Cardiomyopathy (HCM) market in 7MM is expected to change in the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the Hypertrophic Cardiomyopathy market in 7MM. The market size of HCM in the seven major markets was found to be USD 301.3 million in 2020.

 

The United States Market Outlook

This section provides a total of HCM market size and market size by therapies in the United States.

 

The United States accounts for the highest PAH market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Hypertrophic Cardiomyopathy (HCM) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Hypertrophic Cardiomyopathy (HCM) market size and market size by therapies in Japan are also mentioned.

Hypertrophic Cardiomyopathy (HCM) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Hypertrophic Cardiomyopathy (HCM) market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Hypertrophic Cardiomyopathy (HCM) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Hypertrophic Cardiomyopathy (HCM) key players involved in developing targeted therapeutics. Major players Mavacamten (Bristol Myers Squibb), CK-274 (Cytokinetics), LCZ696 (Novartis), IMB-1018972 (Imbria Pharmaceuticals), Trientine (Univar Solutions B.V.) etc being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hypertrophic Cardiomyopathy emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working Hypertrophic Cardiomyopathy (HCM) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or PAH market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Hypertrophic Cardiomyopathy (HCM) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Hypertrophic Cardiomyopathy (HCM) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Hypertrophic Cardiomyopathy (HCM) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hypertrophic Cardiomyopathy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hypertrophic Cardiomyopathy (HCM) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Hypertrophic Cardiomyopathy (HCM) market

Report Highlights

  • In the coming years, Hypertrophic Cardiomyopathy (HCM) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hypertrophic Cardiomyopathy (HCM) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for HCM. The launch of emerging therapies will significantly impact the Hypertrophic Cardiomyopathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HCM
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hypertrophic Cardiomyopathy (HCM) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hypertrophic Cardiomyopathy (HCM) Pipeline Analysis
  • Hypertrophic Cardiomyopathy (HCM) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hypertrophic Cardiomyopathy (HCM) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Hypertrophic Cardiomyopathy (HCM) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hypertrophic Cardiomyopathy (HCM) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hypertrophic Cardiomyopathy (HCM) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Hypertrophic Cardiomyopathy (HCM) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Hypertrophic Cardiomyopathy (HCM) market Size during the forecast period (2021–2030)?
  • At what CAGR, the Hypertrophic Cardiomyopathy (HCM) market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Hypertrophic Cardiomyopathy (HCM) market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Hypertrophic Cardiomyopathy (HCM) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Hypertrophic Cardiomyopathy (HCM)?
  • What is the historical Hypertrophic Cardiomyopathy (HCM) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Hypertrophic Cardiomyopathy(HCM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Hypertrophic Cardiomyopathy (HCM)?
  • Out of all 7MM countries, which country would have the highest prevalent Hypertrophic Cardiomyopathy (HCM) population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Hypertrophic Cardiomyopathy (HCM)?
  • What are the current treatment guidelines for treating Hypertrophic Cardiomyopathy (HCM) in the USA, Europe, and Japan?
  • What are the Hypertrophic Cardiomyopathy (HCM) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hypertrophic Cardiomyopathy (HCM)?
  • How many therapies are developed by each company for the treatment of Hypertrophic Cardiomyopathy (HCM)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Hypertrophic Cardiomyopathy (HCM)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertrophic Cardiomyopathy (HCM) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypertrophic Cardiomyopathy (HCM) and their status?
  • What are the key designations that have been granted for the emerging therapies for Hypertrophic Cardiomyopathy (HCM)?
  • What are the global historical and forecasted markets of Hypertrophic Cardiomyopathy (HCM)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hypertrophic Cardiomyopathy (HCM) market
  • To understand the future market competition in the Hypertrophic Cardiomyopathy (HCM) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hypertrophic Cardiomyopathy (HCM) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hypertrophic Cardiomyopathy (HCM) market
  • To understand the future market competition in the Hypertrophic Cardiomyopathy (HCM) market

1. Key Insights

2. Report Introduction

3. Hypertrophic Cardiomyopathy Market Overview at a Glance

3.1. Market Share (%) Distribution of Hypertrophic Cardiomyopathy in 2018

3.2. Market Share (%) Distribution of Hypertrophic Cardiomyopathy in 2030

4. Executive Summary of Hypertrophic Cardiomyopathy

5. Disease Background and Overview

5.1. Introduction

5.2. Risk Factors

5.3. Symptoms

5.4. Types of HCM

5.5. Molecular Genetics basis

5.6. Pathophysiology

5.6.1. Cardiac abnormalities

5.6.2. Genetic abnormalities

5.7. Disease Stages and Progression

5.7.1. Stages of HCM

5.7.2. Clinical progression of HCM

5.8. Manifestations

5.9. Clinical workup

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Patient Population of HCM

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Hypertrophic Cardiomyopathy in the United States

6.4.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.4.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.4.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.4. Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Germany

6.5.2. France

6.5.2.1. Prevalent Cases of Hypertrophic Cardiomyopathy in France

6.5.2.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in France

6.5.2.3. Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in France

6.5.2.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France

6.5.3. Italy

6.5.3.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.4. Spain

6.5.4.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.2. Diagnosed cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain

6.5.5. United Kingdom

6.5.5.1. Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.6. Japan

6.6.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Japan

6.6.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan

6.6.3. Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan

6.6.4. Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan

7. Treatment and Management

7.1. Pharmacological management

7.2. Non-pharmacologic therapy

7.3. Treatment Guidelines

7.3.1. American Heart Association/American College of Cardiology (AHA/ACC) guideline

7.3.2. European Society of Cardiology (ESC) Guidelines

8. Patient Journey

9. Case Reports

10. Emerging Products

10.1. Mavacamten: Bristol Myers Squibb

10.1.1. Drug Descriptions

10.1.2. Other Developmental Activities

10.1.3. Clinical Development

10.1.4. Clinical Trials Information

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.2. CK-274: Cytokinetics

10.2.1. Drug Description

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. LCZ696: Novartis

10.3.1. Drug Description

10.3.2. Clinical Development

10.3.3. Clinical Trials Information

10.3.4. Product Profile

10.4. IMB-1018972: Imbria Pharmaceuticals

10.4.1. Drug Description

10.4.2. Clinical Development

10.4.3. Clinical Trials Information

10.4.4. Product Profile

10.5. Trientine: Univar Solutions B.V.

10.5.1. Drug Descriptions

10.5.2. Clinical Development

10.5.3. Clinical Trials Information

10.5.4. Safety and Efficacy

10.5.5. Product Profile

11. Organizations contributing towards Hypertrophic Cardiomyopathy

12. Hypertrophic Cardiomyopathy: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Hypertrophic Cardiomyopathy in 7MM

12.3. Market Size of Hypertrophic Cardiomyopathy by Current Therapies

12.5. Market Outlook

12.6. United States Market Size

12.6.1. Total Market Size of Hypertrophic Cardiomyopathy in United States

12.6.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in the United States

12.7. EU-5 Market Size

12.7.1. Germany

12.7.1.1. Total Market size of Hypertrophic Cardiomyopathy in Germany

12.7.1.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in Germany

12.7.2. France

12.7.2.1. Total Market size of Hypertrophic Cardiomyopathy in France

12.7.2.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in France

12.7.3. Italy

12.7.3.1. Total Market size of Hypertrophic Cardiomyopathy in Italy

12.7.3.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in Italy

12.7.4. Spain

12.7.4.1. Total Market size of Hypertrophic Cardiomyopathy in Spain

12.7.4.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in Spain

12.7.5. United Kingdom

12.7.5.1. Total Market size of Hypertrophic Cardiomyopathy in United Kingdom

12.7.5.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in United Kingdom

12.8. Japan

12.8.1. Total Market size of Hypertrophic Cardiomyopathy in Japan

12.8.2. Market Size of Hypertrophic Cardiomyopathy of Therapies in Japan

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Hypertrophic Cardiomyopathy, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Patient Population of Hypertrophic Cardiomyopathy in 7MM (2018–2030)

Table 3: Prevalent Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 4: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 5: Gender-specific diagnosed Cases Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 6: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 7: Prevalent Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 8: Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 9: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 10: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 11: Prevalent Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 12: Diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 13: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 14: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 15: Prevalent Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 16: Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 17: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 18: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 19: Prevalent Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 20: Diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 21: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 22: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 23: Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 24: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 25: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 26: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in United Kingdom (2018–2030)

Table 27: Prevalent Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 28: Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 29: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 30: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 31: Mavacamten, Clinical Trial Description, 2021

Table 32: CK-274, Clinical Trial Description, 2021

Table 33: LCZ696, Clinical Trial Description, 2021

Table 34: IMB-1018972, Clinical Trial Description, 2021

Table 35: Trientine, Clinical Trial Description, 2021

Table 36: Organizations contributing towards Hypertrophic Cardiomyopathy

Table 37: 7 Major Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 38: 7 Major Market Size of Hypertrophic Cardiomyopathy of Current Therapies in USD Million (2018–2030)

Table 39: United States Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 40: United States Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Table 41: Germany Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 42: Germany Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Table 43: France Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 44: France Market Size of Hypertrophic Cardiomyopathy of Current Therapies in USD Million (2018–2030)

Table 45: Italy Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 46: Italy Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Table 47: Spain Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 48: Spain Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Table 49: United Kingdom Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 50: United Kingdom Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Table 51: Japan Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Table 52: Japan Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Schematic representation of two possible sites of obstructive HCM. (A) Sub-aortic obstructive HCM (B) Mid-ventricular obstructive HCM

Figure 2: Locations of genes within the cardiac sarcomere known to cause hypertrophic cardiomyopathy

Figure 3: The ECS Recommended Standardized Diagnosis Work-up for HCM

Figure 4: Diagnosed Patient Population of Hypertrophic Cardiomyopathy in 7MM (2018–2030)

Figure 5: Prevalent Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 6: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 7: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 8: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 9: Prevalent Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 10: Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 11: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 12: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 13: Prevalent Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 14: Diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 15: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 16: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 17: Prevalent Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 18: Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 19: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 20: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 21: Prevalent Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 22: Diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 23: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 24: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 25: Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 26: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 27: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 28: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 29: Prevalent Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 30: Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 31: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 32: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 33: A stepwise approach to the clinical management of patients diagnosed with Hypertrophic Cardiomyopathy

Figure 34: 7 Major Market Size of Hypertrophic Cardiomyopathy in USD Million (2018–2030)

Figure 35: 7 Major Market Size of Hypertrophic Cardiomyopathy of Current Therapies in USD Million (2018–2030)

Figure 36: Market Size of Hypertrophic Cardiomyopathy in the United States, USD Million (2018–2030)

Figure 37: The United States Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Figure 38: Market Size of Hypertrophic Cardiomyopathy in the Germany, USD Million (2018–2030)

Figure 39: The Germany Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Figure 40: Market Size of Hypertrophic Cardiomyopathy in France, USD Million (2018–2030)

Figure 41: The France Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Figure 42: Market Size of Hypertrophic Cardiomyopathy in Italy, USD Million (2018–2030)

Figure 43: The Italy Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Figure 44: Market Size of Hypertrophic Cardiomyopathy in Spain, USD Million (2018–2030)

Figure 45: The Spain Market Size of Hypertrophic Cardiomyopathy of Current Therapies in USD Million (2018–2030)

Figure 46: Market Size of Hypertrophic Cardiomyopathy in the United Kingdom, USD Million (2018–2030)

Figure 47: The United Kingdom Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Figure 48: Market Size of Hypertrophic Cardiomyopathy in Japan, USD Million (2018–2030)

Figure 49: The Japan Market Size of Hypertrophic Cardiomyopathy of Therapies in USD Million (2018–2030)

Bristol Myers Squibb
Cytokinetics
Novartis
Imbria Pharmaceuticals
Univar Solutions B.V.

 

Forward to Friend

Need A Quote